BridgeMD
Compares treatment options for Renal Tumor
Official title Robot-assisted Laparoscopic Partial Nephrectomy Via the Extraperitoneal Approach in the Prone Position Versus the Lateral Position
ClinicalTrials.gov ID: NCT06572501
What this study is testing
- What it's testing
- The goal of this clinical trial is to investigate whether robot-assisted laparoscopic partial nephrectomy by extraperitoneal approach in the prone position had any advantages over the traditional lateral position. The main questions it aims to answer are: Is prone surgery safe and feasible, and what are the advantages over the traditional lateral position?
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- . Patients with preoperative imaging suggestive of renal occupancy;
- . Sex is not limited;
- . Age ≥18 years;
- . Clinical staging consistent with indications for partial nephrectomy;
- . Suitable for robotic-assisted laparoscopic partial nephrectomy via extraperitoneal approach as judged by relevant preoperative clinical data;
You likely can't join if
- . Patients who did not meet the indications for partial nephrectomy and did not undergo robotic-assisted laparoscopic partial nephrectomy via...
- . Patients who refuse to undergo or cannot tolerate surgery in the appropriate position;
- . Patients with incomplete documentation of relevant data to provide accurate demographic, perioperative, and prognostic data;
- . Any condition which, in the opinion of the investigator, may be detrimental to the subject or result in the inability of the subject to meet or...
- . Patients who are unable to provide written informed consent;
See the full eligibility criteria
- . Patients with preoperative imaging suggestive of renal occupancy;
- . Sex is not limited;
- . Age ≥18 years;
- . Clinical staging consistent with indications for partial nephrectomy;
- . Suitable for robotic-assisted laparoscopic partial nephrectomy via extraperitoneal approach as judged by relevant preoperative clinical data;
- . Agree to provide basic clinical information and pathological and imaging data for scientific research and sign an informed consent form;
- . Agree to provide monitoring results during the follow-up recurrence monitoring process.
- . Patients who did not meet the indications for partial nephrectomy and did not undergo robotic-assisted laparoscopic partial nephrectomy via extraperitoneal approach;
- . Patients who refuse to undergo or cannot tolerate surgery in the appropriate position;
- . Patients with incomplete documentation of relevant data to provide accurate demographic, perioperative, and prognostic data;
- . Any condition which, in the opinion of the investigator, may be detrimental to the subject or result in the inability of the subject to meet or perform the requirements of the study;
- . Patients who are unable to provide written informed consent;
The study team makes the final eligibility decision.
Where it's taking place
- Nanjing, Jiangsu, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Nanjing, Jiangsu, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.